Pharmicell Co., Ltd(KR:005690)
â‚©8,930.00+470.00 (+5.56%)
KR:005690
Pharmicell Co., Ltd financials statements
â‚©8,930.00
At close:+470.00 (+5.56%)
Want to see KR:005690 full AI Analyst Report?
Pharmicell Co., Ltd (005690) Ratios
Pharmicell Co., Ltd Ratios
KR:005690's free cash flow for Q2 2026 was ₩9.92B. For the 2026 fiscal year, KR:005690's free cash flow was decreased by ₩-6.51B and operating cash flow was ₩16.43B. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 4.92 | 6.28 | 5.56 | 2.18 | 2.61 |
| Quick Ratio | 4.11 | 3.70 | 2.87 | 1.38 | 1.87 |
| Cash Ratio | 1.47 | 1.08 | 1.77 | 0.50 | 1.05 |
| Solvency Ratio | 1.29 | 0.73 | 0.53 | 0.32 | 0.37 |
| Operating Cash Flow Ratio | 2.09 | 0.46 | 1.52 | 0.28 | -0.21 |
| Short-Term Operating Cash Flow Coverage | 6.84 | 13.52 | 4.84 | 0.47 | -0.31 |
| Net Current Asset Value | â‚© 63.08B | â‚© 35.21B | â‚© 31.04B | â‚© 29.38B | â‚© 34.58B |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.09 | 0.01 | 0.03 | 0.15 | 0.18 |
| Debt-to-Equity Ratio | 0.12 | 0.01 | 0.04 | 0.22 | 0.27 |
| Debt-to-Capital Ratio | 0.11 | 0.01 | 0.04 | 0.18 | 0.21 |
| Long-Term Debt-to-Capital Ratio | 0.06 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.27 | 1.15 | 1.15 | 1.47 | 1.50 |
| Debt Service Coverage Ratio | 6.89 | 26.37 | 2.20 | 0.64 | 0.69 |
| Interest Coverage Ratio | 232.55 | 45.93 | 1.10 | 11.89 | 4.67 |
| Debt to Market Cap | 0.02 | 0.00 | 0.01 | 0.03 | 0.02 |
| Interest Debt Per Share | 245.46 | 13.12 | 65.31 | 293.38 | 315.80 |
| Net Debt to EBITDA | -0.39 | -0.80 | -1.27 | 0.28 | -0.70 |
| Profitability Margins | |||||
| Gross Profit Margin | 43.85% | 32.89% | 26.60% | 39.58% | 44.72% |
| EBIT Margin | 29.61% | 9.82% | 9.96% | 11.16% | 21.49% |
| EBITDA Margin | 32.27% | 14.54% | 15.01% | 14.79% | 24.84% |
| Operating Profit Margin | 29.61% | 7.18% | 1.69% | 14.74% | 15.18% |
| Pretax Profit Margin | 30.52% | 9.66% | 8.42% | 9.92% | 18.24% |
| Net Profit Margin | 35.36% | 9.76% | 6.36% | 13.73% | 18.24% |
| Continuous Operations Profit Margin | 35.36% | 9.76% | 6.36% | 13.73% | 18.24% |
| Net Income Per EBT | 115.86% | 101.07% | 75.61% | 138.41% | 100.00% |
| EBT Per EBIT | 103.06% | 134.55% | 497.59% | 67.27% | 120.20% |
| Return on Assets (ROA) | 25.62% | 6.38% | 3.87% | 7.33% | 9.86% |
| Return on Equity (ROE) | 32.56% | 7.32% | 4.45% | 10.78% | 14.80% |
| Return on Capital Employed (ROCE) | 24.51% | 5.08% | 1.12% | 10.54% | 11.09% |
| Return on Invested Capital (ROIC) | 23.45% | 5.05% | 0.76% | 8.79% | 7.53% |
| Return on Tangible Assets | 26.56% | 6.76% | 4.12% | 7.75% | 10.55% |
| Earnings Yield | 4.62% | 1.27% | 0.96% | 1.28% | 1.21% |
| Efficiency Ratios | |||||
| Receivables Turnover | 5.24 | 3.87 | 7.16 | 5.00 | 5.38 |
| Payables Turnover | 21.74 | 14.11 | 23.23 | 13.69 | 34.19 |
| Inventory Turnover | 4.01 | 2.20 | 1.98 | 1.59 | 1.55 |
| Fixed Asset Turnover | 2.42 | 1.52 | 1.38 | 1.63 | 2.66 |
| Asset Turnover | 0.72 | 0.65 | 0.61 | 0.53 | 0.54 |
| Working Capital Turnover Ratio | 1.94 | 1.71 | 1.62 | 1.63 | 1.35 |
| Cash Conversion Cycle | 143.81 | 234.31 | 219.87 | 275.74 | 292.04 |
| Days of Sales Outstanding | 69.61 | 94.27 | 50.99 | 72.93 | 67.80 |
| Days of Inventory Outstanding | 90.99 | 165.90 | 184.59 | 229.47 | 234.91 |
| Days of Payables Outstanding | 16.79 | 25.86 | 15.71 | 26.66 | 10.68 |
| Operating Cycle | 160.60 | 260.17 | 235.58 | 302.40 | 302.71 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 684.05 | 58.30 | 198.12 | 132.00 | -87.12 |
| Free Cash Flow Per Share | 559.87 | -14.00 | 97.14 | -184.18 | -159.18 |
| Dividend Paid and CapEx Coverage Ratio | 4.74 | 0.63 | 1.96 | 0.42 | -1.21 |
| Capital Expenditure Coverage Ratio | 5.51 | 0.81 | 1.96 | 0.42 | -1.21 |
| Operating Cash Flow Coverage Ratio | 2.81 | 5.10 | 3.90 | 0.47 | -0.30 |
| Operating Cash Flow to Sales Ratio | 0.36 | 0.05 | 0.21 | 0.13 | -0.10 |
| Free Cash Flow Yield | 3.85% | -0.17% | 1.56% | -1.71% | -1.22% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 21.62 | 78.48 | 103.83 | 78.02 | 82.77 |
| Price-to-Sales (P/S) Ratio | 7.65 | 7.66 | 6.61 | 10.71 | 15.10 |
| Price-to-Book (P/B) Ratio | 7.04 | 5.75 | 4.62 | 8.41 | 12.25 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 25.95 | -591.48 | 64.13 | -58.37 | -81.98 |
| Price-to-Operating Cash Flow Ratio | 21.24 | 142.02 | 31.45 | 81.44 | -149.80 |
| Price-to-Earnings Growth (PEG) Ratio | 0.04 | 1.03 | -1.84 | -6.19 | 1.03 |
| Enterprise Value Multiple | 23.30 | 51.89 | 42.75 | 72.70 | 60.09 |
| Enterprise Value | 857.78B | 489.26B | 360.82B | 647.03B | 773.33B |
| EV to EBITDA | 23.30 | 51.89 | 42.75 | 72.70 | 60.09 |
| EV to Sales | 7.52 | 7.54 | 6.42 | 10.75 | 14.93 |
| EV to Free Cash Flow | 25.53 | -582.46 | 62.29 | -58.59 | -81.04 |
| EV to Operating Cash Flow | 20.89 | 139.86 | 30.54 | 81.75 | -148.09 |
| Tangible Book Value Per Share | 1970.75 | 1347.20 | 1254.38 | 1226.75 | 986.17 |
| Shareholders’ Equity Per Share | 2064.04 | 1440.56 | 1348.20 | 1278.64 | 1065.48 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -0.16 | -0.01 | 0.24 | -0.38 | 0.00 |
| Revenue Per Share | 1900.49 | 1080.78 | 942.89 | 1003.73 | 864.30 |
| Net Income Per Share | 671.97 | 105.51 | 60.00 | 137.79 | 157.66 |
| Tax Burden | 1.16 | 1.01 | 0.76 | 1.38 | 1.00 |
| Interest Burden | 1.03 | 0.98 | 0.85 | 0.89 | 0.85 |
| Research & Development to Revenue | 0.06 | 0.12 | 0.12 | 0.11 | 0.13 |
| SG&A to Revenue | 0.03 | 0.05 | 0.05 | 0.04 | 0.04 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 1.02 | 0.55 | 3.30 | 0.73 | -0.55 |
Currency in KRW
